Evidence map›Paper›PMID 34057619›Full record

ArticleBulletin of experimental biology and medicine2021

Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs.

I V Kholodenko, Ya S Kim, A M Gisina, A Yu Lupatov, R V Kholodenko, K N Yarygin

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.International journal of molecular sciences · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

I V KholodenkoV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia. irkhol@yandex.ru.
Ya S KimV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
A M GisinaV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
A Yu LupatovV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
R V KholodenkoM. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
K N YaryginV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
Institute of Biomedical Chemistry · RUInstitute of Bioorganic Chemistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A correlation was found between chemoresistance of HT-29CD133

Indexed as

AdenocarcinomaColorectal NeoplasmsAC133 AntigenCell Line, TumorDrug Resistance, NeoplasmHT29 CellsHumansNeoplastic Stem CellsAC133 Antigencancer stem cellsCD133chemoresistancechemotherapeutic agentscolorectal cancer

Identifiers

PMID34057619
OpenAlexW3164605567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.